TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32857590

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified),
Number of subjects: 0
Study: 32858352

Group type: EXPERIMENTAL
Intervention: Sleep bruxism (SB) self-report and polysomnography (PSG) assessment
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Insomnia syndrome
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Apnea/hypopnea index (AHI) above 30
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Being male, overweight, or obese
Number of subjects: 1042
Study: 32858478

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to chemotherapy
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to anthracycline
Number of subjects: 132
Study: 32858531

Group type: EXPERIMENTAL
Intervention: Nitroglycerin in oxytocin-desensitized myometrium
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nitroglycerin in oxytocin-naïve myometrium
Number of subjects: 17

Group type: COMPARATOR
Intervention: No nitroglycerin in oxytocin-naïve myometrium
Number of subjects: 17

Group type: COMPARATOR
Intervention: No nitroglycerin in oxytocin-desensitized myometrium
Number of subjects: 17
Study: 32858583

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 20
Study: 32858582

Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (US) treatment
Number of subjects: 99
Study: 32858584

Group type: EXPERIMENTAL
Intervention: Postdural puncture headache
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (uneventful labour epidurals)
Number of subjects: 132
Study: 32858752

Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring (FGM)
Number of subjects: 111
Study: 32859321

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Fish oil intake
Number of subjects: 229
Study: 32860168

Group type: EXPERIMENTAL
Intervention: Poziotinib treatment
Number of subjects: 106
Study: 32860184

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Control (no terlipressin)
Number of subjects: 1644
Study: 32860424

Group type: EXPERIMENTAL
Intervention: Benzodiazepines and Z-drugs (BZD/Z)
Number of subjects: 1024
Study: 32860500

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-induced deep sedation (MOAA/S = 0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (random forest)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EEG spectral features (delta, theta, beta bands)
Number of subjects: 30
Study: 32860553

Group type: EXPERIMENTAL
Intervention: Ankle NIBP measurement
Number of subjects: 97
Study: 32860956

Group type: EXPERIMENTAL
Intervention: MVR (Multivisceral resection)
Number of subjects: 435

Group type: COMPARATOR
Intervention: DP without MVR (Control)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Pancreatic fistula rates
Number of subjects: 435
Study: 32861651

Group type: EXPERIMENTAL
Intervention: 3D mechanical wave velocity mapping technique
Number of subjects: 15
Study: 32861656

Group type: EXPERIMENTAL
Intervention: CCTA-derived fractional flow reserve (FFR)
Number of subjects: 4737

Group type: EXPERIMENTAL
Intervention: CCTA and FFR
Number of subjects: 4737
Study: 32862518

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) in HFrEF
Number of subjects: 5391

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) in HFpEF
Number of subjects: 5391

Group type: EXPERIMENTAL
Intervention: Physical independence summary score in HFpEF
Number of subjects: 5391

Group type: EXPERIMENTAL
Intervention: KCCQ clinical summary score in both HF groups
Number of subjects: 5391
Study: 32862715

Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffolds loaded with autologous bone marrow mononuclear cells (BMMCs) implanted into the cleaned site
Number of subjects: 7
Study: 32863013

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic testing for aneuploidy (PGT-A) assay
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Trophectoderm biopsy
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (no biopsy)
Number of subjects: 402
Study: 32863016

Group type: EXPERIMENTAL
Intervention: Volume expansion with 250 ml of saline 0.9% over 10 min
Number of subjects: 109
Study: 32863171

Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 58
Study: 32863279

Group type: EXPERIMENTAL
Intervention: Comprehensive evaluation of multiterritorial artery stenosis and plaque using advanced vascular imaging techniques
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Brain MRI and CT angiography
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Prospective collection of cardiovascular/cerebrovascular events and cognitive assessments
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Blood and urine samples for biomarker testing
Number of subjects: 3067
Study: 32863639

Group type: EXPERIMENTAL
Intervention: Protocolized sedative weaning
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 32863882

Group type: EXPERIMENTAL
Intervention: 12-week Resistance Training (RT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 50
Study: 32864144

Group type: EXPERIMENTAL
Intervention: Local PBMT-sMF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-local PBMT-sMF
Number of subjects: 30
Study: 32864392

Group type: EXPERIMENTAL
Intervention: LSTM (Long Short-Term Memory) recurrent neural network
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dynamic Time Warping (DTW)
Number of subjects: 2
Study: 32864448

Group type: EXPERIMENTAL
Intervention: High-speed barbecue maneuver (HSB)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modified Lempert maneuver (ML)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham maneuver (SM)
Number of subjects: 54
Study: 32864480

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 32864604

Group type: EXPERIMENTAL
Intervention: Food insecurity screening using the American Academy of Pediatrics 2-question food insecurity screen
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding food insecurity
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Employment status assessment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Participation in the WIC program
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Screening of families at FQHC
Number of subjects: 200
Study: 32864625

Group type: EXPERIMENTAL
Intervention: Alpelisib, a selective inhibitor of PI3Kα
Number of subjects: 0
Study: 32865059

Group type: EXPERIMENTAL
Intervention: Self-Management of Type 1 Diabetes for Chinese Adults (SMOD-CA) scale
Number of subjects: 243
Study: 32865097

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using Cockcroft-Gault equation
Number of subjects: 14980

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using Modification of Diet in Renal Disease equation
Number of subjects: 14980

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on creatinine
Number of subjects: 14980

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) calculated using CKD-EPI equation based on cystatin C
Number of subjects: 14980
Study: 32865293

Group type: EXPERIMENTAL
Intervention: Hetrombopag 2.5 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hetrombopag 5 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hetrombopag 7.5 mg/day
Number of subjects: 32
Study: 32865454

Group type: EXPERIMENTAL
Intervention: Wixela Inhub Dry Powder Inhaler
Number of subjects: 0
Study: 32865505

Group type: EXPERIMENTAL
Intervention: i-Matter mobile health texting tool
Number of subjects: 282
Study: 32865809

Group type: EXPERIMENTAL
Intervention: Remdesivir plus standard of care (SOC)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo plus standard of care (SOC)
Number of subjects: 237
Study: 32866032

Group type: EXPERIMENTAL
Intervention: Nonacog gamma (BAX 326, RIXUBIS)
Number of subjects: 0
Study: 32866179

Group type: EXPERIMENTAL
Intervention: Full-field optical coherence tomography (FF-OCT)
Number of subjects: 16
Study: 32866202

Group type: EXPERIMENTAL
Intervention: Tablet App for the Simplified Gestational Age Score (T-SGAS)
Number of subjects: 8591
Study: 32866219

Group type: EXPERIMENTAL
Intervention: Prediction model including 11 variables associated with hypotension
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Prediction model excluding unstable patients
Number of subjects: 934
Study: 32866540

Group type: EXPERIMENTAL
Intervention: Risk factors for CKD progression
Number of subjects: 3379

Group type: EXPERIMENTAL
Intervention: Cardiac markers, plasma CXCL12, urinary NGAL
Number of subjects: 3379
Study: 32866988

Group type: EXPERIMENTAL
Intervention: Epidermal allografts
Number of subjects: 8
Study: 32867535

Group type: EXPERIMENTAL
Intervention: Headache onset within 7 days of head injury
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Headache onset between 8 days and 3 months after head injury
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Pre-existing migraine before head injury
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Headache onset based on sex, headache phenotype, or mechanism of injury
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Headache phenotype comparison within 7 days
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Recommendation regarding ICHD-3 diagnostic criteria
Number of subjects: 193
Study: 32867573

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-HNE protein adducts detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human needle-biopsy liver samples
Number of subjects: 0
Study: 32867679

Group type: EXPERIMENTAL
Intervention: Measurement of mid-arm circumference (MAC)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Weight measurement
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: BMI measurement
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Standard finger cuffs
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Obese parturients
Number of subjects: 300
Study: 32867698

Group type: EXPERIMENTAL
Intervention: Low-dose Sabin IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium-dose Sabin IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose Sabin IPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Sabin IPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Salk IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antibody titer < 1:8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antibody titer 1:8 ~ < 1:32
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antibody titer ≥ 1:32
Number of subjects: 0
Study: 32867715

Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with FOLFOXIRI/bevacizumab
Number of subjects: 70
Study: 32867719

Group type: EXPERIMENTAL
Intervention: Group penalized generalized estimating equation (PGEE) method for ERP data analysis
Number of subjects: 0
Study: 32867720

Group type: EXPERIMENTAL
Intervention: ADPKD patients (17)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Non-ADPKD patients (16)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls (18)
Number of subjects: 51
Study: 32867853

Group type: EXPERIMENTAL
Intervention: Participants' clinical evaluation including DMFT and caries free rates.
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Higher DMFT score associated with personal variables.
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Lower caries free rates associated with personal variables.
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Linear regression for total DMFT.
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Logistic regression for caries free.
Number of subjects: 702
Study: 32868037

Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg IV infusion over 60 min
Number of subjects: 30
Study: 32868326

Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Number of subjects: 0
Study: 32868346

Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin 500 mg-1 g four times a day
Number of subjects: 159
Study: 32868349

Group type: EXPERIMENTAL
Intervention: Metformin as first-line glucose-lowering therapy
Number of subjects: 15992

Group type: EXPERIMENTAL
Intervention: Non-insulin monotherapy at second line
Number of subjects: 15992

Group type: EXPERIMENTAL
Intervention: Older age (≥75 years) and history of chronic kidney disease
Number of subjects: 15992

Group type: COMPARATOR
Intervention: Patients from Africa
Number of subjects: 15992
Study: 32868537

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control Episodic Thinking (CET)
Number of subjects: 67
Study: 32869689

Group type: EXPERIMENTAL
Intervention: Patient portal use for telerehabilitation
Number of subjects: 0
Study: 32869840

Group type: EXPERIMENTAL
Intervention: Fatty liver disease (FLD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Non-black race
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: ALT levels
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Metabolic risks (hypertension, hyperlipidemia, diabetes family history)
Number of subjects: 114
Study: 32869924

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF)
Number of subjects: 0
Study: 32870132

Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast MRI
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intravoxel incoherent motion MRI
Number of subjects: 94
Study: 32870139

Group type: EXPERIMENTAL
Intervention: Chest CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: RT-PCR
Number of subjects: 0
Study: 32870250

Group type: EXPERIMENTAL
Intervention: Mavorixafor 400 mg once daily
Number of subjects: 8
Study: 32870265

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 1124
Study: 32870266

Group type: EXPERIMENTAL
Intervention: Rare sequence variants (RSVs) in IHH-associated genes
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 106
Study: 32870269

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 92
Study: 32871021

Group type: EXPERIMENTAL
Intervention: Acupuncture or acupressure plus analgesia
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Aromatherapy plus analgesia
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Massage (foot and hand) plus analgesia
Number of subjects: 3076

Group type: EXPERIMENTAL
Intervention: Music plus analgesia
Number of subjects: 3076
Study: 32871506

Group type: EXPERIMENTAL
Intervention: Parental supply of sips
Number of subjects: 1910

Group type: EXPERIMENTAL
Intervention: Supply of sips from other sources
Number of subjects: 1910

Group type: EXPERIMENTAL
Intervention: Supply of whole drinks by parents or others
Number of subjects: 1910

Group type: EXPERIMENTAL
Intervention: Larger quantities of alcohol supply
Number of subjects: 1910
Study: 32871584

Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PD-L1/PD-L2 copy gain or amplification
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Spatial analysis of tumor microenvironment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Unbiased clustering of spatially resolved immune signatures
Number of subjects: 5
Study: 32871668

Group type: EXPERIMENTAL
Intervention: Self-reported anxiety
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Conscientiousness (personality dimension)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 107
Study: 32873058

Group type: EXPERIMENTAL
Intervention: Prognostic awareness (PA)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Age as a predictor of PA
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Goals of care discussions (GOCD)
Number of subjects: 377
Study: 32873121

Group type: EXPERIMENTAL
Intervention: Automated analyses using artificial intelligence-based software for biventricular parameters including ejection fraction (EF)
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Manual assessments of biventricular parameters including ejection fraction (EF)
Number of subjects: 1017
Study: 32873131

Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DCB followed by Pulsar-18 bare metal stent
Number of subjects: 120
Study: 32873157

Group type: EXPERIMENTAL
Intervention: Multicontext (MC) approach
Number of subjects: 8
Study: 32873195

Group type: EXPERIMENTAL
Intervention: Application of the '5-2-1' screening criteria
Number of subjects: 0
Study: 32873237

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Thoracic computed tomography (CT)
Number of subjects: 113
Study: 32873270

Group type: EXPERIMENTAL
Intervention: Dose-dense TPF (ddTPF) chemotherapy with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day 1, followed by 48-h continuous infusion of 2500 mg/m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy.
Number of subjects: 58
Study: 32873343

Group type: EXPERIMENTAL
Intervention: Chidamide, decitabine, cytarabine, aclarubicin, and G-CSF (CDCAG)
Number of subjects: 93
Study: 32873586

Group type: EXPERIMENTAL
Intervention: ABCD, DiaRem, Ad-DiaRem, DiaBetter, and individualized metabolic surgery scores
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Diabetes duration alone
Number of subjects: 363
Study: 32873668

Group type: EXPERIMENTAL
Intervention: Type I interferon gene signature (IFNGS) status measured by a four-gene test, with scores compared to a pre-established cut-off.
Number of subjects: 900
Study: 32873915

Group type: EXPERIMENTAL
Intervention: Carfilzomib combined with cyclosporine and methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32873924

Group type: EXPERIMENTAL
Intervention: CRISPR-directed gene editing targeting the beta globin gene.
Number of subjects: 0
Study: 32874062

Group type: EXPERIMENTAL
Intervention: Alarm symptoms
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Gastroscopic screening based on alarm symptoms
Number of subjects: 381
Study: 32874376

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) achieved by 4 cycles of 5-minute inflation of a cuff on the left upper arm to 200 mm Hg followed by 5-minute deflation.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group with a deflated cuff placed on the left arm for 40 minutes.
Number of subjects: 101
Study: 32874573

Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg dose)
Number of subjects: 3
Study: 32874593

Group type: EXPERIMENTAL
Intervention: Onymous Arm (descriptive norms messages with personal identification)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Anonymous Arm (descriptive norms messages without personal identification)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Onymous Arm
Number of subjects: 311

Group type: COMPARATOR
Intervention: Anonymous Arm
Number of subjects: 311
Study: 32874839

Group type: EXPERIMENTAL
Intervention: Topical atropine 0.125%
Number of subjects: 96
Study: 32875141

Group type: EXPERIMENTAL
Intervention: Gut microbiome intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient feeding with controlled metabolic phenotyping
Number of subjects: 0
Study: 32875267

Group type: EXPERIMENTAL
Intervention: Complementary food supplementation
Number of subjects: 0
Study: 32875289

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA treatment
Number of subjects: 730
Study: 32875313

Group type: EXPERIMENTAL
Intervention: High GFR (GFR ≥ 52)
Number of subjects: 1782

Group type: COMPARATOR
Intervention: Low GFR (GFR < 52)
Number of subjects: 1782
Study: 32875390

Group type: EXPERIMENTAL
Intervention: Post-procedural MTT (Mean Transit Time)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Post-procedural PBF (Perfusion Blood Flow)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Post-procedural PBV (Perfusion Blood Volume)
Number of subjects: 5
Study: 32876113

Group type: EXPERIMENTAL
Intervention: ICU survival at 28 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hospital survival at 60 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Use of advanced life support
Number of subjects: 300
Study: 32876349

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg IV every 4 weeks
Number of subjects: 2243
Study: 32876903

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 32876998

Group type: EXPERIMENTAL
Intervention: Perceived substance use norms among jailed women
Number of subjects: 205
Study: 32877212

Group type: EXPERIMENTAL
Intervention: Multiple-Breath Washout
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 0
Study: 32877220

Group type: EXPERIMENTAL
Intervention: Admission hematocrit (HCT) in MOF group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Admission hematocrit (HCT) in non-MOF group
Number of subjects: 57
Study: 32877254

Group type: EXPERIMENTAL
Intervention: Estradiol (E2; 4-µg and 10-µg) softgel vaginal insert
Number of subjects: 0
Study: 32877349

Group type: EXPERIMENTAL
Intervention: Use of the official Singapore government's WhatsApp channel
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Increased exposure to COVID-19 news
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Increased time spent receiving COVID-19 updates
Number of subjects: 1145